Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
358.33
+5.51 (1.56%)
At close: Jun 26, 2026, 4:00 PM EDT
357.67
-0.66 (-0.18%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Amgen Employees
Amgen had 31,500 employees as of December 31, 2025. The number of employees increased by 3,500 or 12.50% compared to the previous year.
Employees
31,500
Change (1Y)
3,500
Growth (1Y)
12.50%
Revenue / Employee
$1,181,587
Profits / Employee
$247,619
Market Cap
193.39B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31,500 | 3,500 | 12.50% |
| Dec 31, 2024 | 28,000 | 1,300 | 4.87% |
| Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
| Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
| Dec 31, 2021 | 24,200 | -100 | -0.41% |
| Dec 31, 2020 | 24,300 | 900 | 3.85% |
| Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
| Dec 31, 2018 | 21,500 | 700 | 3.37% |
| Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
| Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
| Dec 31, 2015 | 17,900 | 0 | - |
| Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
| Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
| Dec 31, 2012 | 18,000 | 200 | 1.12% |
| Dec 31, 2011 | 17,800 | 400 | 2.30% |
| Dec 31, 2010 | 17,400 | 200 | 1.16% |
| Dec 31, 2009 | 17,200 | 300 | 1.78% |
| Dec 31, 2008 | 16,900 | -600 | -3.43% |
| Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
| Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
| Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
| Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
| Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
| Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
| Dec 31, 2001 | 7,700 | 400 | 5.48% |
| Dec 31, 2000 | 7,300 | 900 | 14.06% |
| Dec 31, 1999 | 6,400 | 900 | 16.36% |
| Dec 31, 1998 | 5,500 | 192 | 3.62% |
| Dec 31, 1997 | 5,308 | 662 | 14.25% |
| Dec 31, 1996 | 4,646 | 600 | 14.83% |
| Dec 31, 1995 | 4,046 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
AMGN News
- 17 hours ago - European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked - WSJ
- 19 hours ago - EMA recommends revoking marketing authorisation for Amgen's rare-disease drug - Reuters
- 1 day ago - FDA works to pull Amgen’s Tavneos off the market, Bloomberg says - TheFly
- 9 days ago - The Healthcare M&A Wave - Forbes
- 10 days ago - Amgen price target raised to $303 from $295 at Mizuho - TheFly
- 12 days ago - Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PRNewsWire
- 13 days ago - Drugmakers race to find a place in the next wave of obesity drugs - CNBC
- 15 days ago - Amgen taps research firm to reassess Tavneos data - Reuters